問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result > Study Site

Study Site



Tri-Service General Hospital

  • 0

    Total Beds

  • 0

    Total Doctors

  • 112Taipei CityBeitou

Recruiting Trial

245Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

802Cases

2010-11-01 - 2011-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2008-06-01 - 2009-01-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2019-09-25 - 2021-09-24

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2020-08-01 - 2021-08-19

Phase III

A Phase III, Prospective, Multi-center, Double-blind, Randomized, Parallel-Group Study to Compare the Efficacy and Safety of Pitavastatin 2 mg/ Ezetimibe 10 mg with Pitavastatin and Ezetimibe in Patients with Primary Hypercholesterolemia or Mixed Dyslipidemia

  • Condition/Disease

    Primary Hypercholesterolemia/Mixed Dyslipidemias

  • Test Drug

    1PC111

Participate Sites
23Sites

Not yet recruiting4Sites

Recruiting19Sites

2012-07-01 - 2019-08-31

Phase II/III

A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Condition/Disease

    A Randomized, Double-Blind, Active Drug Controlled Study to Assess the Efficacy of HUEXC030 as Add-on Excipient to Eradicate Anti-Tuberculosis Drugs Induced Liver Injury in Subjects with Pulmonary Tuberculosis

  • Test Drug

    Isoniazid tablet formulated with excipient HUEXC030

Participate Sites
13Sites

Terminated13Sites

2016-02-01 - 2017-01-31

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Terminated1Sites

2015-06-01 - 2017-02-28

Phase III

A Phase III, Multi-Center, Randomized, Double-blind, Placebo Controlled, Two-way Cross-over Clinical Study to Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents with ADHD

  • Condition/Disease

    ADHD (Attention Deficit Hyperactivity Disorder)

  • Test Drug

    ORADUR-Methylphenidate

Participate Sites
4Sites

Terminated4Sites

2010-12-01 - 2012-07-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2011-10-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

1 77 78 79 80 81
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB